Logo

Ipsen Signs an Exclusive WW Collaboration with Accent to Develop and Commercialize METTL3 Program

Share this
Ipsen Signs an Exclusive WW Collaboration with Accent to Develop and Commercialize METTL3 Program

Tuba Khan

Ipsen Signs an Exclusive WW Collaboration with Accent to Develop and Commercialize METTL3 Program

Shots:

  • Accent to receive ~$446M including up front- pre-clinical- clinical- regulatory- and sales-based milestone along with royalties
  • Ipsen obtains an exclusive license to develop- manufacture and commercialize a pre-clinical stage METTL3-inhibitor program
  • The collaboration combines Accent’s expertise in RMP-targeting therapeutics with Ipsen’s capabilities to develop and commercialize transformative oncology medicines for the treatment of AML

Click here to­ read the full press release/ article | Ref: Businesswire | Image: Pharma Boardroom

Click Here

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family